SP-002 (Sunny Pharmtech)

SP-002 is a small molecule oral tablet formulation currently in development by Sunny Pharmtech for the treatment of Wilson's Disease. Wilson's Disease is a rare autosomal recessive genetic disorder characterized by the toxic accumulation of copper in the liver, brain, and other vital organs. SP-002 has been designated as an orphan drug, reflecting its target for a rare disease population. As Sunny Pharmtech is a Contract Development and Manufacturing Organization (CDMO) specializing in high-potency APIs and complex formulations, SP-002 likely represents a generic version or a specialized formulation of an established therapy for copper chelation or the inhibition of copper absorption. The product is currently in the R&D phase of Sunny Pharmtech's development pipeline, which follows a CDMO-specific pathway involving pilot batches and bioequivalence studies.